

LeenLife Pharma International Inc.

Suite 380 - 580 Hornby Street
Vancouver, B.C., V6C 3B6



NEWS RELEASE

LeenLife Pharma International Closes Private Placement

December 11, 2017

CSE - LLP

Vancouver, B.C. – LeenLife Pharma International Inc. (the “**Company**”) is pleased to announce that it has closed a non-brokered private placement offering (the “**Private Placements**”) of Units (as defined below).

On December 4, 2017 the Company announced a non-brokered private placement for gross proceeds of \$1,500,000. The non-brokered private placement, in accordance with rules of Canadian Securities Exchange, consisted of 15,000,000 units at \$0.10 per unit for total gross proceeds of \$1,500,000. Each unit consists of one common share and one transferable share purchase warrant, each warrant exercisable into one additional common share at a price of \$0.15 per share for three years from closing.

The Company wishes to increase and close the Private Placement to 19,025,000 units on the same terms and conditions as noted above and has raised a total gross proceeds of \$1,902,500. Finders’ fee for the placement will be paid in cash for total of \$68,500.

Each Unit was sold at a price of \$0.10 and consists of one common share of the Company (each, a “**Common Share**”), and one common share purchase warrant (each a “**Warrant**”). Each Warrant will be exercisable into one Common Share at a price of \$0.15 per Common Share for a period of three (3) years from December 11, 2017. Of the total, approximately 1,900,000 units were purchased by management of LeenLife.

All securities issued are subject to a statutory hold period of four months and one day from the distribution date. The proceeds of the private placement will be used for general working capital, purchase of a BioCube plant and expanding the company's presence and operations in Europe and North America.

About LeenLife

LeenLife has a proprietary process to isolate omega-3 fatty acids from flax seeds. LeenLife products have been developed and researched for over 17 years. For additional information see our website at <http://leenlifepharma.com>.

For more information, please contact:

Stan Lis, CEO

Tel: 604 764-0518

E-mail: slis@leenlifepharma.com

Further information about the Company is available on www.SEDAR.com under the Company's profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.